In Germany, ibogaine (Ibogain) is a controlled substance listed in Anlage II of the Betäubungsmittelgesetz (BtMG), meaning unlicensed possession, supply, or administration is a criminal offence, though licensed use for research purposes is legally possible. Last verified: April 2026.

Current Legal Status

Ibogaine is explicitly named in Anlage II of the BtMG — Germany's primary narcotics law. Understanding what Anlage II means is important:

  • Anlage II (non-marketable, limited-purpose): Substances in this schedule cannot be commercially marketed or dispensed to patients as medicines. However, unlike the stricter Anlage I, Anlage II substances may be used under a licence issued by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for scientific research, manufacturing of approved products, or other specifically permitted purposes.
  • Anlage I (non-marketable, near-absolute prohibition): For comparison, substances in Anlage I face broader restrictions with almost no permitted use pathways. Ibogaine does not sit in this more restrictive schedule.

In practice, the Anlage II classification means:

  • Unlicensed possession of ibogaine is a criminal offence under §29 BtMG, punishable by up to five years' imprisonment or a fine.
  • Unlicensed supply, import, export, or administration carries penalties of up to five years (or up to fifteen years for commercial or gang-related trafficking under §30 BtMG).
  • There is no recognised medical or therapeutic exemption for clinical ibogaine treatment in Germany currently. No approved ibogaine-containing medicine exists on the German or EU market.
  • Licensed research institutions may apply to BfArM for authorisation to handle ibogaine for scientific purposes.

Tabernanthe iboga (the iboga plant itself) is not scheduled under the BtMG. Possession of the plant or its root bark is not directly criminalised under narcotics law, though extracting or isolating ibogaine from it would constitute manufacture of a controlled substance and trigger BtMG penalties.

Religious or ceremonial exemptions: No religious carve-out exists in German law for ibogaine. The BtMG does not provide a ceremony-based exemption analogous to those recognised for peyote use in certain jurisdictions. Courts have not established a precedent recognising such a defence in German proceedings.

Treatment Centers

No licensed ibogaine treatment clinics operate legally within Germany. The Anlage II classification and the absence of an approved ibogaine medicine mean that offering ibogaine-assisted therapy to patients is not lawful without a BfArM research licence — and clinical treatment falls outside the scope of such licences.

Underground or informal ibogaine sessions do occur but carry serious legal risk for both providers and, potentially, participants. Quality control and medical safety oversight in such settings are absent.

German residents who seek legal ibogaine treatment typically travel abroad. See our full clinic directory for licensed and established centres in jurisdictions where ibogaine treatment is permitted.

How People Access Ibogaine in Germany

The following is a factual description of how access occurs. It is not a recommendation to pursue any of these routes.

  • Medical travel: The most common route for German residents is travelling to countries where ibogaine clinics operate legally, such as Portugal, the Netherlands, Mexico, or South Africa. Treatment costs, travel, and accommodation are borne by the individual; German health insurance does not cover ibogaine treatment.
  • Underground domestic sessions: Informal ibogaine sessions conducted by unlicensed providers exist in Germany, as in many countries. Participation exposes individuals to legal risk and, critically, to serious safety risks given the absence of medical oversight.
  • Research participation: Individuals may occasionally be eligible to participate in BfArM-authorised or internationally registered clinical trials involving ibogaine or related compounds. These are rare and subject to strict eligibility criteria. Checking registries such as ClinicalTrials.gov or the EU Clinical Trials Register is the appropriate way to identify open studies.
  • Iboga plant material: Because Tabernanthe iboga is unscheduled, some individuals obtain root bark through online vendors. However, any attempt to extract ibogaine constitutes a BtMG offence, and consuming unprocessed plant material carries the same cardiac and physiological risks as purified ibogaine without the benefit of dose accuracy.

Recent Legal Developments

Germany has not moved to reschedule ibogaine or create a therapeutic access pathway as of April 2026. Several contextual developments are worth noting:

  • Psychedelic research momentum: Academic and clinical interest in psychedelic-assisted therapies has grown significantly in Germany. Psilocybin and MDMA research programmes are active at institutions including the Charité in Berlin and LMU Munich. This broader shift in research culture may eventually create conditions for ibogaine research applications, but no ibogaine-specific trial has been registered in Germany to date.
  • Cannabis legalisation (2024): Germany's partial legalisation of cannabis for adult use under the Konsumcannabisgesetz (KCanG), which took effect in April 2024, demonstrated political willingness to revise drug scheduling. However, this reform has not extended to ibogaine or other psychedelic compounds.
  • EU regulatory environment: Ibogaine remains unapproved as a medicine across the European Union. The European Medicines Agency (EMA) has not received a marketing authorisation application for an ibogaine product. Any EU-level approval would be a prerequisite for lawful patient access across member states, including Germany.
  • International research pressure: Published data from Stanford University and other institutions on ibogaine's efficacy for traumatic brain injury and opioid use disorder have increased public and policy discussion in Germany, though no legislative proposals have been introduced.

Risks of Seeking Treatment in Germany

Important safety and legal notice: Ibogaine carries a narrow therapeutic index and documented cardiac risks, including QT interval prolongation and potentially fatal arrhythmias. These risks apply regardless of the legal jurisdiction in which treatment occurs. In Germany, additional risks are specific to the legal context.

  • Criminal liability: Participating in an unlicensed ibogaine session, even as a recipient rather than a provider, may expose individuals to prosecution under §29 BtMG. German courts have discretion in how they handle possession cases, and outcomes vary by Bundesland and circumstances, but the legal risk is real.
  • Provider accountability: Underground providers operate without professional licensing, mandatory reporting obligations, or liability insurance. In the event of a medical emergency, providers may be reluctant to call emergency services for fear of criminal exposure, potentially delaying life-saving care.
  • No quality standards: Without regulatory oversight, ibogaine purity, dosage accuracy, and pharmaceutical grade cannot be verified. Adulterated or misdosed preparations significantly increase cardiac risk.
  • No pre-treatment screening: Licensed clinics abroad typically conduct ECG screening, contraindication assessments, and drug interaction reviews before administering ibogaine. Underground sessions typically do not.
  • Emergency services interaction: If emergency services are called during an adverse event, first responders will be responding to what is, legally, a narcotics incident. This has implications for how the situation is handled and for any subsequent legal proceedings.

Frequently Asked Questions

Ibogaine (Ibogain) is listed in Anlage II of the BtMG — not Anlage I. This distinction is legally significant. Anlage I substances face near-absolute prohibition with almost no permitted use pathway. Anlage II substances are non-marketable as medicines but can be handled under a BfArM licence for scientific research or authorised manufacturing. In practice, ibogaine is still effectively prohibited for clinical or personal use, but the research pathway is technically open in a way it would not be under Anlage I.
No. Unlicensed possession of ibogaine is a criminal offence under §29 BtMG. Penalties include fines or up to five years' imprisonment. No personal use exemption or tolerance policy equivalent to some other European countries' cannabis policies applies to ibogaine in Germany.
Yes — Tabernanthe iboga, the plant from which ibogaine is derived, is not scheduled under the BtMG. Possessing the plant or its root bark is not in itself a narcotics offence. However, processing or extracting ibogaine from the plant would constitute manufacturing a controlled substance under Anlage II and would trigger BtMG penalties. Additionally, consuming root bark to achieve psychoactive effects from its naturally occurring ibogaine content remains legally ambiguous and carries the same physiological risks as purified ibogaine.
No. There are no licensed ibogaine treatment clinics in Germany. The Anlage II classification prohibits commercial or clinical administration without a BfArM research licence, and no such licence has been granted for patient-facing ibogaine therapy. German residents seeking legal ibogaine treatment must travel to jurisdictions where it is permitted. Our clinic directory lists verified international options.
Yes, in principle. Because ibogaine is in Anlage II rather than Anlage I, institutions can apply to BfArM for a licence to handle ibogaine for approved scientific research. The application process is demanding and approval is not guaranteed, but the legal pathway exists. Researchers at universities or approved institutions would need to demonstrate scientific justification, appropriate security, and compliance with all BtMG handling requirements.
There are no active legislative proposals to legalise or reclassify ibogaine for therapeutic use in Germany as of April 2026. While Germany's 2024 cannabis reform and growing European interest in psychedelic-assisted therapy signal a shifting political climate, ibogaine faces a more complex path than compounds like psilocybin due to its cardiac risk profile and the lack of large-scale Phase III trial data. Any therapeutic legalisation would also likely require prior EMA approval of an ibogaine-based medicine.
Receiving ibogaine treatment in a jurisdiction where it is legal does not constitute a criminal offence under German law — the treatment occurred outside German territory. However, bringing ibogaine or iboga products back into Germany would constitute import of a controlled substance under §29 BtMG and is a serious criminal offence. Customs authorities may screen returning travellers, and declaring or being found with ibogaine at the border carries significant legal risk.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.